Evercore ISI analyst Vijay Kumar upgraded Novocure to In Line from Underperform with an unchanged price target of $33. The firm says “nothing incremental here for us,” noting that it is moving to the sidelines now that the stock has hit its price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVCR:
